Improving treatment for serious lung infections using aerosol therapy
Aerosol delivery of combinational therapeutics targeting deadly lung infections
This study is looking at a new way to deliver antibiotics directly to the lungs to help fight tough bacterial infections, using a special spray that combines two types of antibiotics, which could lead to better treatment and fewer side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project ID | NIH-11019751 on NIH RePORTER |
What this research studies
This research focuses on enhancing the delivery of antibiotics directly to the lungs to combat multidrug-resistant bacterial infections. By using aerosolized combinations of polymyxins and aminoglycosides, the study aims to optimize drug delivery and minimize toxicity. The approach involves systematic evaluations of how these drugs interact in the lungs, particularly their effects on lung cells. Patients may benefit from improved treatment efficacy and reduced side effects compared to traditional methods.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with pulmonary infections caused by multidrug-resistant Gram-negative bacteria.
Not a fit: Patients with non-bacterial lung infections or those not affected by antibiotic-resistant bacteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from severe lung infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Previous research has shown promise in using aerosolized therapies for lung infections, but this specific combination approach is novel and has not been extensively tested.
Where this research is happening
West Lafayette, United States
- Purdue University — West Lafayette, United States (Active)
Researchers
- Principal investigator: Zhou, Qi — Purdue University
- Study coordinator: Zhou, Qi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.